Dr Andrea Gonzalez-Munoz | Research Associate

Dr Andrea Gonzalez-Munoz, Research Associate, Medimmune

After completing a PhD in Immunogenetics at the University of Cambridge in 2000 (Babraham Institute), Andrea obtained a postdoctoral fellow position to focus on the identification and characterisation of genes that contributes to Diabetes Type I susceptibility at the JDRF/WT Diabetes and Inflammation Laboratory, CIMR (Cambridge Institute of Medical Research), Addenbrooke’s Hospital, Cambridge, UK. In 2007, Andrea joined the Technology Department at Cambridge Antibody Technology (CAT) that later become MedImmune. For several years, Andrea has been working in phenotypic screening covering novel target discovery, protein engineering and novel therapeutic platforms in the Antibody Discovery and Protein Engineering Department at MedImmune.


EAC 2017 Day 2, Wednesday 1st November 2017 @ 11:45

A novel antibody drug conjugate targeting the Trypanosoma brucei haptoglobin-haemoglobin receptor to treat sleeping sickness

  • Taking advantage of receptor-mediated nutrient uptake by trypanosomes, toxin-conjugated monoclonal antibodies recognising these receptors could be used to target and deliver a toxin to the parasite The T. b. brucei haptoglobin-haemoglobin receptor
  • Monoclonal antibodies generated against the HpHbR N-terminal were conjugated to Pyrrolobenzodiazepine (PBD) toxins leading to targeted cell killing of trypanosomes at picomolar concentrations

back to speakers